Analyst Price Target is $26.50
▲ +286.86% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Frequency Therapeutics in the last 3 months. The average price target is $26.50, with a high forecast of $56.00 and a low forecast of $9.00. The average price target represents a 286.86% upside from the last price of $6.85.
Current Consensus is
The current consensus among 4 contributing investment analysts is to buy stock in Frequency Therapeutics. This Buy consensus rating has held steady for over two years.
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. The company was incorporated in 2014 and is headquartered in Woburn, Massachusetts.